All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Marek TrněnýDuring the 2022 EBMT Annual Meeting, the Lymphoma Hub was pleased to speak with Marek Trněný, Charles University Prague, CZ. We asked, EBMT 2022: What are the highlights for the treatment of lymphoma?
EBMT 2022: What are the highlights for the treatment of lymphoma?
Trněný begins by discussing the presidential abstract on pre treatment with immune checkpoint inhibitors and differing outcomes in relapsed/refractory Hodgkin lymphoma following allogeneic stem cell transplant. Trněný goes on to explore other registry analyses and studies presented at EBMT before outlining results, study designs, and outcome data about highlights in the lymphoma setting, such as the ZUMA-7 trial.
Your opinion matters
On average, how many patients with chronic lymphocytic leukemia do you see in a month?